Global Neuroendocrine Tumors (NET) Market Spotlight 2020-2028
04 mars 2021 06h48 HE
|
Research and Markets
Dublin, March 04, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Neuroendocrine tumors (NET)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the...
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
21 sept. 2020 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference
26 nov. 2019 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
12 nov. 2019 16h04 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
03 sept. 2019 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
13 août 2019 16h14 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
29 juil. 2019 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors
16 juil. 2019 09h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 16, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
21 mai 2019 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
13 mai 2019 16h11 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...